Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 4/20 | 0.56 |
| ▸ | MAOA | P21397 | 3/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3891084 | 0.84 | HTR2A (0.61) | SLC6A4LOXL2MAOBMAOATAAR1 | |
| SCHEMBL13459307 | 0.84 | LOXL2 (0.54) | SLC6A4LOXL2MAOBMAOATAAR1 | |
| Hydrochloric Acid SCHEMBL18223661 | 0.82 | LOXL2 (0.52) | SLC6A4LOXL2MAOBMAOATAAR1 | |
| SCHEMBL332623 | 0.82 | MAOA (0.63) | SLC6A4MAOBMAOAMEN1KMT2A | |
| SCHEMBL10055053 | 0.82 | ALDH1A1 (0.57) | SLC6A4MAOBMAOAMEN1KMT2A | |
| SCHEMBL12522062 | 0.82 | ABAT (0.64) | SLC6A4LOXL2MAOBMAOATAAR1 | |
| SCHEMBL3889607 | 0.81 | NPC1 (0.66) | SLC6A4MAOBMAOAMEN1KMT2A | |
| SCHEMBL7591596 | 0.81 | SLC6A4 (0.62) | SLC6A4MAOBMAOAMEN1KMT2A | |
| SCHEMBL28084553 | 0.80 | MAOA (0.61) | SLC6A4MAOBMAOAMEN1KMT2A | |
| SCHEMBL7591594 | 0.79 | MAOB (0.56) | SLC6A4MAOBMAOAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-2316846-B1 | Spatially-defined macrocyclic compounds useful for drug discovery | OCERA THERAPEUTICS INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10040751-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2210612-B1 | Macrocyclic antagonists of the motilin receptor | OCERA THERAPEUTICS INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | OCERA THERAPEUTICS LLC | 2016-08-04 | — | — | US | disclosed |
| US-9181298-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| EP-1720836-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-1720836-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1648922-A4 | SPATIALLY-DEFINED MACROCYCLIC COMPOUNDS USEFUL FOR DRUG DISCOVERY | TRANZYME PHARMA INC (CA) | 2006-08-23 | — | — | EP | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| EP-1648922-A1 | SPATIALLY-DEFINED MACROCYCLIC COMPOUNDS USEFUL FOR DRUG DISCOVERY | Tranzyme Pharma Inc. (CA) | 2006-04-26 | — | — | EP | disclosed |
| EP-1633774-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR | Tranzyme Pharma Inc. (CA) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050137127-A1 | Spatially-defined macrocyclic compounds useful for drug discovery | TRANZYME PHARMA INC (CA) | 2005-06-23 | — | — | US | disclosed |
| US-20050054562-A1 | Macrocyclic antagonists of the motilin receptor | TRANZYME PHARMA INC. (CA) | 2005-03-10 | — | — | US | disclosed |
| WO-2005012331-A1 | SPATIALLY-DEFINED MACROCYCLIC COMPOUNDS USEFUL FOR DRUG DISCOVERY | TRANZYME PHARMA (CA) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004111077-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR | TRANZYME PHARMA INC. (CA) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040751-B2 | Intermediates for macrocyclic compounds | MLNR, CCKAR, CHRM2 | SLC6A4 994/4885LOXL2 4685/4885MAOB 1341/4885 |
| US-20050137127-A1 | Spatially-defined macrocyclic compounds useful for drug discovery | MLNR, GIPR, CCKAR | SLC6A4 1563/4885LOXL2 4007/4885MAOB 2371/4885 |
| US-20050054562-A1 | Macrocyclic antagonists of the motilin receptor | MLNR, GIPR, CCKAR | SLC6A4 1145/4885LOXL2 4323/4885MAOB 1855/4885 |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | SLC6A4 994/4885LOXL2 4685/4885MAOB 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.